Compare Crispr Therapeutics AG (CRSP) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Nvidia Corp — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Nvidia Corp trades at $211.18 (market cap $5.13T). The key difference: Nvidia Corp is far larger — about 1032.2× Crispr Therapeutics AG's market cap, and Nvidia Corp pays a 0.47% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | NVDA | |
|---|---|---|
Market Cap | $4.97B | $5.13T |
Sector | Health | Technology |
52-Week High | $76.78 | $235.75 |
52-Week Low | $44.34 | $165.17 |
Enterprise Value | $3.32B | $5.06T |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
NVIDIA (NVDA) trades at $203.53, down 3.52% over the past 24 hours. The stock exhibits a bullish technical signal with strong moving average alignment, while oscillators remain neutral. Fundamentally, the company reported record revenue of $130.50 billion in 2025, with a net income margin of 62.97% and robust cash flow from operations of $64.09 billion. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.87 surpassing the $1.76 estimate. The upcoming Q2 2026 earnings report, expected at $2.09 EPS, is a key near-term catalyst.
The outlook for NVDA remains positive, driven by sustained AI chip demand and strong execution, though risks include heightened competition and market volatility. Analyst consensus is strongly bullish with a $325.86 price target, implying significant upside. Investors should weigh the company's exceptional profitability and growth trajectory against valuation multiples that reflect high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
